1.

Distribution of human papillomavirus genotypes in women with cervical cancer in Slovenia.

Ninety-four point two percent of cervical cancer cases were HPV positive in a representative sample of cervical cancer cases. Histopathological characteristics of cervical cancer cases were also described. Human papillomavirus genotypes found were: HPV 16, 18, 33, 45, 31, 51, 58, 59, 35, 52, 73 and 82.

COBISS.SI-ID: 25690841

2.

Comparison of paired cervical scrape and tumor tissue samples for detection of human papillomaviruses in patients with cervical cancer.

We compared how cervical scrape samples correlate with cervical tissue samples in detection of HPV genotypes in patients with cervical cancer. The overall correlation was 98.75%. We have found that cervical scrape samples are equally accurate as tissue samples for detection of HPV genotypes in cervical cancer.

COBISS.SI-ID: 26239449

3.

Genomic variants of human papillomavirus genotypes 16, 18, and 33 in women with cervical cancer in Slovenia.

A total of 40 isolates of HPV 16, 20 isolates of HPV 18 and 11 isolates of HPV 33 obtained from Slovenian women with cervical cancer were included in the study. The genomic diversity was investigated within LCR, E6 and E7 genomic regions. The majority of HPV 16 and HPV 18 isolates from Slovenian patients with cervical cancer belonged to European phylogenetic branches. Prototye and non-prototype HPV 33 genomic variants were equally distributed.

COBISS.SI-ID: 27716825

4.

Pre-vaccination distribution of HPV genotypes in women with cervical intraepithelial neoplasia grade 3 (CIN 3) lesions in Slovenia.

In this study we wanted to establish the pre-vaccination distribution of HPV genotypes in Slovenian women with CIN 3 lesions. A total of 261 cervical swabs collected from women with histologically confirmed CIN 3 lesions were analyzed. Of 261 samples, 253 (96.9%) were HPV positive. The most common HPV genotype was HPV 16 (59.0%), followed by HPV 31, HPV 33, HPV 58, and HPV 51. The high proportion of CIN 3 lesions caused by HPV 16 and HPV 18 should further support the recent decision to include the prophylactic vaccination against HPV in the national vaccination program in Slovenia.

COBISS.SI-ID: 25819609

5.

The Abbott real-time HPV test: evaluation of specificity and sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid capture 2 test.

We evaluated specificity and sensitivity for cervical carcinoma and CIN3 of the Abbott Real-Time test in comparison with the hc2 test. Specificity of the Real-Time assay was evaluated on samples with previously determined hc2 false-positive results; all were negative for 14 hr-HPV. Sensitivity of RealTime was evaluated on cervical specimens from women with cervical carcinoma and CIN3 lesions. The Real-Time test showed high specificity. Sensitivity of the Real-Time assay was comparable to hc2. The Real-Time test is an important new method applicable to cervical carcinoma screening program.

COBISS.SI-ID: 26215897